April 04, 2018
Megan Pace Joins Moderna as Chief Corporate Affairs Officer
February 20, 2018
Newly Published Data Highlight Moderna’s mRNA Platform in Advancing Prophylactic Vaccine for Cytomegalovirus (CMV) Infections
February 01, 2018
Moderna Closes $500 Million Equity Financing
January 08, 2018
Moderna Announces an Array of Clinical Advances and Outlines 2018 Priorities; 19 Development Candidates, including 10 Clinical Programs, Highlight Productivity of mRNA Platform
January 03, 2018
Dr. John Mendlein Joins Moderna as President, Corporate and Product Strategy
January 02, 2018
Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference
December 19, 2017
Moderna Publishes Preclinical Data in Cell Reports on mRNA Therapeutic to Treat Rare Liver Disease Methylmalonic Acidemia (MMA), A Disorder of Organic Acid Metabolism
November 15, 2017
Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors
November 01, 2017
Moderna Announces New Collaboration with AstraZeneca to Co-Develop and Co-Commercialize Relaxin mRNA Therapeutic for Heart Failure
October 19, 2017
Moderna Named One of Global Biopharmaceutical Industry’s Top Employers in Science Magazine’s Annual Survey

Pages